Market Chatter: Hillhouse Cashes In on BeiGene Rally; Backs Hengrui Pharma IPO

MT Newswires Live

May 16

Hillhouse Capital sold HK$2.08 billion worth of BeiGene (SHA:688235, HKG:6160) shares at HK$130 each as it cashed in on the surge of the latter's shares, YiCai Global reported Thursday.

The sale trimmed Hillhouse Capital's stake in the drug company to 4.89% from 6.03%, according to the report.

Hillhouse Capital also joined GIC and UBS as a cornerstone investor in Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) upcoming 13.1 billion-yuan secondary listing on the Hong Kong bourse, YiCai Global wrote.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2535353805"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535353805\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535353805?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-16 14:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535353805","market":"sh","top_or_hot":-1,"title":"Market Chatter: Hillhouse Cashes In on BeiGene Rally; Backs Hengrui Pharma IPO","media":"MT Newswires Live","content":"<html><body><p> Hillhouse Capital sold HK$2.08 billion worth of BeiGene (SHA:688235, HKG:6160) shares at HK$130 each as it cashed in on the surge of the latter's shares, YiCai Global reported Thursday.</p><p>The sale trimmed Hillhouse Capital's stake in the drug company to 4.89% from 6.03%, according to the report.</p><p>Hillhouse Capital also joined GIC and UBS as a cornerstone investor in Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) upcoming 13.1 billion-yuan secondary listing on the Hong Kong bourse, YiCai Global wrote.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: Hillhouse Cashes In on BeiGene Rally; Backs Hengrui Pharma IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: Hillhouse Cashes In on BeiGene Rally; Backs Hengrui Pharma IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-16 14:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hillhouse Capital sold HK$2.08 billion worth of BeiGene (SHA:688235, HKG:6160) shares at HK$130 each as it cashed in on the surge of the latter's shares, YiCai Global reported Thursday.</p><p>The sale trimmed Hillhouse Capital's stake in the drug company to 4.89% from 6.03%, according to the report.</p><p>Hillhouse Capital also joined GIC and UBS as a cornerstone investor in Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) upcoming 13.1 billion-yuan secondary listing on the Hong Kong bourse, YiCai Global wrote.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2535353805","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535353805","pubTimestamp":1747378237,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hillhouse Capital sold HK$2.08 billion worth of BeiGene  shares at HK$130 each as it cashed in on the surge of the latter's shares, YiCai Global reported Thursday.The sale trimmed Hillhouse Capital's stake in the drug company to 4.89% from 6.03%, according to the report.Hillhouse Capital also joined GIC and UBS as a cornerstone investor in Jiangsu Hengrui Pharmaceuticals'  upcoming 13.1 billion-yuan secondary listing on the Hong Kong bourse, YiCai Global wrote.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","688235":"百济神州","BK0060":"抗癌","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK1161":"生物科技","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK0183":"MSCI概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK1583":"高瓴概念","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","06160":"百济神州","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0188":"融资融券","BK0239":"医药制造","BK0012":"证金概念","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK1500":"做空集合股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK0028":"国家队","BK0196":"行业龙头","BK1588":"回港中概股"},"translate_title":"市场热议：高瓴从百济神州反弹中获利；支持恒瑞医药IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":0.9,"688235":0.9,"06160":1},"content_text":"Hillhouse Capital sold HK$2.08 billion worth of BeiGene (SHA:688235, HKG:6160) shares at HK$130 each as it cashed in on the surge of the latter's shares, YiCai Global reported Thursday.The sale trimmed Hillhouse Capital's stake in the drug company to 4.89% from 6.03%, according to the report.Hillhouse Capital also joined GIC and UBS as a cornerstone investor in Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) upcoming 13.1 billion-yuan secondary listing on the Hong Kong bourse, YiCai Global wrote.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}